Antiplatelet and anticoagulation therapy
https://libcat.nshealth.ca/en/permalink/provcat32336
Albert Ferro, David A. Garcia, editors.
--London:
Springer
, c2013.
- Available Online
- View e-Book
- Location
- Online
Aspirin has been in clinical use for over 100 years, making it one of the oldest commonly used drugs in medicine, and is now predominantly used as an antiplatelet agent. Major new antiplatelet drug classes have recently become available for the clinician that offer the promise of major improvements in the treatment and prevention of arterial thrombotic disease. In the field of anticoagulation, the vitamin K antagonists such as warfarin have not been available for as long as aspirin in the antip…
- Available Online
- View e-Book
- Other Authors
- Ferro, Albert
- Garcia, David A
- Responsibility
- Albert Ferro, David A. Garcia, editors
- Place of Publication
- London
- Publisher
- Springer
- Date of Publication
- c2013
- Physical Description
- 1 online resource (x, 247 p. : 37 ill., 26 ill. in color)
- Series Title
- Current cardiovascular therapy
- ISBN
- 9781447142973
- Subjects (MeSH)
- Arterial Occlusive Diseases - drug therapy
- Blood Coagulation Factor Inhibitors - therapeutic use
- Platelet Aggregation Inhibitors - therapeutic use
- Thrombosis - drug therapy
- Subjects (LCSH)
- Cardiology
- Abstract
- Aspirin has been in clinical use for over 100 years, making it one of the oldest commonly used drugs in medicine, and is now predominantly used as an antiplatelet agent. Major new antiplatelet drug classes have recently become available for the clinician that offer the promise of major improvements in the treatment and prevention of arterial thrombotic disease. In the field of anticoagulation, the vitamin K antagonists such as warfarin have not been available for as long as aspirin in the antiplatelet field, and have also had very little in the way of competition until recently; although a number of parenteral anticoagulants have been available, the vitamin K antagonists have been the only orally active anticoagulant drugs. The last few years have seen the arrival of new drug classes, the orally active direct thrombin inhibitors and factor Xa antagonists, which offer a number of advantages, but not without important drawbacks. In the face of these important advances in both antiplatelet and anticoagulant therapy, clinicians often feel confused, even overwhelmed, as to what is now available and which drugs are useful (and indicated) in which circumstances. Antiplatelet and Anticoagulant Therapy is designed with such people in mind. It is written in an easy-to-follow format and with many illustrations to aid clarity and the assimilation of information. Each chapter is written by established authorities in their fields who are also experienced in explaining often complex concepts. The result is a unique book which is not only comprehensive but also clear and useful for the busy medical practitioner.
- Contents
- Antiplatelet agents: current and novel -- Antiplatelet Drug Resistance and Variability in Response: The Role of Antiplatelet Therapy Monitoring -- Anticoagulant Drugs: Current and Novel -- Antithrombotic Treatment of Cardiovascular Disease -- Approaches to the Prophylaxis and Treatment of Venous and Cardiac Thromboembolic Disease -- Index.
- Format
- e-Book
- Location
- Online
Handbook of antiplatelet therapy
https://libcat.nshealth.ca/en/permalink/provcat21182
Cohen, Marc.
--London, England:
Martin Dunitz
, 2003.
- Call Number
- WG 300 C678h 2003
- Location
- Dickson Building
- Halifax Infirmary
- Call Number
- WG 300 C678h 2003
- Author
- Cohen, Marc
- Place of Publication
- London, England
- Publisher
- Martin Dunitz
- Date of Publication
- 2003
- Physical Description
- 181 p.
- ISBN
- 1841840807
- Subjects (MeSH)
- Coronary Arteriosclerosis - drug therapy
- Platelet Aggregation Inhibitors - therapeutic use
- Blood Platelets - physiology
- Format
- Book
- Location
- Dickson Building
- Halifax Infirmary
- Copies
- 2
- Loan Period
- 3 weeks
Pharmacological treatment of acute coronary syndromes
https://libcat.nshealth.ca/en/permalink/provcat33393
Pablo Avanzas, Peter Clemmensen, editors.
--London:
Springer ; ISCP
, c2014.
- Available Online
- View e-Book
- Location
- Online
Cardiovascular pharmacotherapy is a fast-moving and complex discipline within cardiology in general. New studies, trials and indications are appearing on a regular basis. This series, and this particular title within the series, is designed to establish the baseline level of knowledge that a cardiovascular professional needs to know on a day-to-day basis. The information within is designed to allow readers to learn quickly and with certainty the mode of action, the possible adverse effects, and…
- Available Online
- View e-Book
- Corporate Author
- International Society of Cardiovascular Pharmacotherapy
- Other Authors
- Avanzas, Pablo
- Clemmensen, Peter
- Responsibility
- Pablo Avanzas, Peter Clemmensen, editors
- Place of Publication
- London
- Publisher
- Springer ; ISCP
- Date of Publication
- c2014
- Physical Description
- 1 online resource (xvi, 245 pages)
- Series Title
- Current cardiovascular therapy
- ISBN
- 9781447154242 (electronic bk.)
- 9781447154235
- Subjects (MeSH)
- Acute Coronary Syndrome - drug therapy
- Anticoagulants - therapeutic use
- Platelet Aggregation Inhibitors - therapeutic use
- Subjects (LCSH)
- Cardiovascular pharmacology
- Heart - Diseases - Chemotherapy
- Coronary heart disease
- Electrocardiography
- Pharmacology
- Acute coronary syndrome - Diagnosis
- Abstract
- Cardiovascular pharmacotherapy is a fast-moving and complex discipline within cardiology in general. New studies, trials and indications are appearing on a regular basis. This series, and this particular title within the series, is designed to establish the baseline level of knowledge that a cardiovascular professional needs to know on a day-to-day basis. The information within is designed to allow readers to learn quickly and with certainty the mode of action, the possible adverse effects, and the management of patients prescribed these drugs.
- Contents
- 1. Anti-ischemic Therapy -- 2. Antiaggregant Therapy: New potent P2Y12 inhibitors -- 3. Anticoagulation Therapy: Heparins and Factor Xa inhibitors -- 4. Secondary prevention in ACS: The role of novel oral anticoagulants -- 5. American versus European guidelines: Critical appraisal -- 6. Triple therapy: Risky but sometimes necessary -- 7. Management of bleeding complications.
- Format
- e-Book
- Location
- Online
Nova Scotia Health Authority. QEII. Cardiology.
Halifax, NS:
Nova Scotia Health Authority
, 2019.
- Pamphlet Number
- 1496
- Available Online
- View Pamphlet
Ticagrelor is a medicine used along with low dose Aspirin to reduce your risk of having a heart attack. You should not take Ticagrelor if you have or had a current bleeding problem such as bleeding from a stomach ulcer or if you have severe liver disease. Instructions for how to take and store this medicine as well as drug interactions and foods to avoid are discussed. Missed dose instructions are given. This pamphlet also describes warnings and possible side effects.
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. QEII. Cardiology
- Alternate Title
- Brilinta
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2019
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document ([4] p.) : digital, PDF file
- Subjects (MeSH)
- Platelet Aggregation Inhibitors - therapeutic use
- Adenosine - therapeutic use
- Cardiovascular Diseases - prevention & control
- Myocardial Infarction - prevention & control
- Pulmonary Embolism - prevention & control
- Subjects (LCSH)
- Adenosine
- Anticoagulants (Medicine)
- Cardiovascular system--Diseases--Prevention
- Myocardial infarction--Prevention
- Abstract
- Ticagrelor is a medicine used along with low dose Aspirin to reduce your risk of having a heart attack. You should not take Ticagrelor if you have or had a current bleeding problem such as bleeding from a stomach ulcer or if you have severe liver disease. Instructions for how to take and store this medicine as well as drug interactions and foods to avoid are discussed. Missed dose instructions are given. This pamphlet also describes warnings and possible side effects.
- Responsibility
- Prepared by: Cardiology
- Pamphlet Number
- 1496
